SAR 114137

Drug Profile

SAR 114137

Alternative Names: SAR114137

Latest Information Update: 02 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class
  • Mechanism of Action Cathepsin K inhibitors; Cathepsin S inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neuropathic pain; Pain

Most Recent Events

  • 31 Mar 2012 Discontinued - Phase-I for Neuropathic pain in Europe (unspecified route)
  • 31 Mar 2012 Discontinued - Phase-I for Pain in Europe (unspecified route)
  • 31 Dec 2011 Sanofi completes a phase I trial in Pain and Neuropathic pain in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top